EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Brensocatib in non-cystic fibrosis bronchiectasis: neutrophil serine protease modulation, clinical evidence, and therapeutic positioning

Muhammad Saeed Akhtar

Expert Review of Clinical Pharmacology · 2026

DOI: 10.1080/17512433.2026.2739561 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2026. Verfasst von Muhammad Saeed Akhtar. Beteiligte Einrichtung: Department of Chemistry, Yeungnam University, Gyeongsan, Republic of Korea. Hauptthemen laut MEDLINE: Bronchiectasis. Die Arbeit nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Non-cystic fibrosis bronchiectasis (NCFB) is a chronic airway disease characterized by recurrent infection, mucus retention, neutrophilic inflammation, and pulmonary exacerbations. Brensocatib is an oral, selective, reversible dipeptidyl peptidase 1 (DPP1) inhibitor that reduces neutrophil serine protease activation and has received regulatory approval for non-cystic fibrosis bronchiectasis in patients aged 12 years and older. AREAS COVERED: This review evaluates the mechanism, clinical pharmacology, efficacy, safety, regulatory status, and therapeutic positioning of brensocatib. Literature published through 30 June 2026 was identified through PubMed, Scopus, and SciFinder-n, supplemented by prescribing information, regulatory documents, bronchiectasis guidelines, and evidence from the phase 2 WILLOW and phase 3 ASPEN trials. EXPERT OPINION: Brensocatib is a mechanism-directed preventive therapy for NCFB; the evidence base is strongest in patients with recent pulmonary exacerbations, while exact sequencing relative to macrolides and inhaled antibiotics remains uncertain. It should be integrated with airway-clearance and infection-directed management rather than viewed as a stand-alone intervention. Its long-term value will depend on appropriate patient selection, dermatologic and periodontal monitoring, affordability, comparative effectiveness, and real-world evidence on exacerbations, antibiotic use, lung-function trajectories, and patient-centered outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BronchiectasisHumansNeutrophilsAnimalsSerine ProteasesPatient SelectionChild

Stichwörter der Autor:innen

BrensocatibDPP1 inhibitionbronchiectasisdipeptidyl peptidase 1neutrophil elastaseneutrophil serine proteasespulmonary exacerbation

Substanzen

Serine Proteases

Autor:innen und Institutionen

  • Department of Chemistry, Yeungnam University, Gyeongsan, Republic of Korea.

Zitieren

APA

Akhtar, M. S. (2026). Brensocatib in non-cystic fibrosis bronchiectasis: neutrophil serine protease modulation, clinical evidence, and therapeutic positioning. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2739561

Vancouver

Akhtar MS. Brensocatib in non-cystic fibrosis bronchiectasis: neutrophil serine protease modulation, clinical evidence, and therapeutic positioning. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2739561

BibTeX
@article{Akhtar2026,
  author = {Akhtar, Muhammad Saeed},
  title = {Brensocatib in non-cystic fibrosis bronchiectasis: neutrophil serine protease modulation, clinical evidence, and therapeutic positioning},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2026},
  doi = {10.1080/17512433.2026.2739561}
}
Kostenlos starten →